Literature DB >> 23613543

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.

Deborah Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23613543     DOI: 10.1136/bmj.f2607

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Authors:  Hsin-Chun Chou; Wen-Wen Chen; Fei-Yuan Hsiao
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 2.  Benefits of healthy adipose tissue in the treatment of diabetes.

Authors:  Subhadra C Gunawardana
Journal:  World J Diabetes       Date:  2014-08-15

3.  LINAGLIPTIN-INDUCED PANCREATITIS.

Authors:  Jorge Esteban Mosquera; Nancy Torres; Jorge Restrepo; Carlos Ruz-Pau; Sowmya Suryanarayanan
Journal:  AACE Clin Case Rep       Date:  2020-11-06

4.  Canagliflozin-induced pancreatitis: a rare side effect of a new drug.

Authors:  Mudit Chowdhary; Ahmad A Kabbani; Akansha Chhabra
Journal:  Ther Clin Risk Manag       Date:  2015-06-26       Impact factor: 2.423

5.  Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis.

Authors:  Shimin Chen; Enfa Zhao; Wenfei Li; Jiehong Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.